http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106117340-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 |
| filingDate | 2016-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106117340-B |
| titleOfInvention | Tumor necrosis factor β analog, its conjugate and its medical usage |
| abstract | This application involves tumor necrosis factor β analog, its conjugate and its medical usages.Specifically, amino acid sequence is selected from: SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4 this application involves a kind of engineered tumor necrosis factor β analog；Further relate to the conjugate of PEG molecule and tumor necrosis factor β or PEG molecule and the formation of tumor necrosis factor β analog covalent bond.There is better internal stability according to the conjugate of the application, therefore reduce the frequency of intravenously administrable, reduce the dosage of drug, while also reducing the acute toxicity of drug, increase antineoplaston effect.In animal model, the conjugate of the application can prevent or treat malignant tumour, and have advantageous medical prospect. |
| priorityDate | 2016-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.